After a 16-year wait for the US Food and Drug Administration (FDA) to approve its lung imaging tool, Cyclopharm (ASX:CYC) is ...

All participants will be in a listen-only mode until the question-and-answer session of the conference. This call is being ...

Q4 2024 Earnings Call Transcript January 22, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.04, ...

Powers Health opened a new sleep clinic in the fast-growing town of Winfield. St. Mary Medical Center Sleep Medicine Services is now accepting patients at a new Winfield location in the Powers Health ...

I'm at that age, 67 going in 68, where it is reasonable to yell at the clouds. Which, come to think of it, may be a good ...

As Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & ...

If you’re short on time, Stoner recommends the three-minute step test as another alternative that offers a score of aerobic ...

ResMed’s stock has surged but faces potential risks from GLP-1 drugs. Find out why RMD stock remains a Hold as investors ...

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...

A recent trial showed that nicotinamide riboside supplementation might reduce airway inflammation in patients with COPD who ...

The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...

“Patients with mild-to-moderate COPD who have low exercise tolerance are likely to experience poor respiratory health outcomes,” the investigators concluded. “Exercise tolerance may be considered one ...